supported by the National Natural Science Foundation of China(32071432,32171434,82272943,32322048);the Youth Science and Technology Talents in Shanghai Sail Plan of China(21YF1456000);Young Elite Scientists Sponsorship Program by CAST(2022QNRC001);Shanghai Rising-Star Program(22QA1411100);the Youth Innovation Promotion Association(CAS2021276);the Sanofi Scholarship Program,Shanghai Committee of Science and Technology,China(21Y11913400);Guangdong High-level New R&D Institute,China(2019B090904008);Guangdong High-level Innovative Research Institute,China(2021B0909050003).
Histone deacetylase inhibitors(HDACis)are important drugs for cancer therapy,but the indistinct resistant mechanisms of solid tumor therapy greatly limit their clinical application.In this study we conducted HDACi-per...
This study was supported by the National Natural Science Foundation of China(81871653,82072286 and 82073251);Natural Science Foundation of Chongqing(cstc2020jcyj-msx mX0159,cstc2018jcyjAX0254 and cstc2019jcyj-msxmX0587);Chongqing Medical Science Project(2018MSXM065);Technology Research Project of Chongqing Municipal Education Commission(KJQN201900449;KJZD-M202000401);Scientific Research Innovation Project for Postgraduates in Chongqing(CYS19193 and CYB19168).
Background and Aims:Chronic hepatitis B virus(HBV)infection is a global public health challenge.HBV reactivation usually occurs in cancer patients after receiving cytotoxic chemotherapy or immunosuppressive therapies....
supported by funding from the National Natural Science Foundation of China(No.21272134);Shenzhen Municipal Government(No.CXB201104210014A and20150113A0410006)
By combining the core pharmacophores of HDAC inhibitor vorinostat and kinase inhibitors vandetanib,BMS-690514,neratinib,and TAK-285 with 1,2,3-triazole as linker,eight novel 6-substituted-4-aminoquinazolin derivatives...
This work was supported by grants from the National Natural Science Foundation of China (81372391, 81071856, 81228016, and 81250110552), Shanghai Science and Technology Program (12410705100), and Shanghai Tenth People's Hospital Funds (040113015).
In the present study, we investigated the interactions between proteasome inhibitor carfllzomib (CFZ) and histone deacety lase inhibitor vorinostat in Jurkat Tleukemia ceils. Coexposure of cells to minimally lethal ...
Background: Histone deacetylase inhibitors (HDACI) are promising class of drugs acting as antiproliferative agents by promoting differentiation as well as inducing apoptosis. Vorinostat (suberoylanilide hydroxamic aci...
Vorinostat, a histone deacetylase (HDAC) inhibitor currently in a clinical phase III trial for multiple myeloma (MM) patients, has been reported to cause bone loss. The purpose of this study was to test whether, a...